PDF(Pubmed)
Abstract：
OBJECTIVE: The present study was intended to fabricate chitosan (Ch)-tamarind gum polysaccharide (TGP) polyelectrolyte complex stabilized cubic nanoparticles of simvastatin and evaluate their potential against human breast cancer cell lines.
METHODS: The antisolvent precipitation method was used for formulation of nanoparticles. Factorial design (32) was utilized as a tool to analyze the effect of Ch and TGP concentration on particle size and entrapment efficiency of nanoparticles.
RESULTS: Formulated nanoparticles showed high entrapment efficiency (67.19±0.42-83.36±0.23%) and small size (53.3-383.1 nm). The present investigation involved utilization of two biological membranes (egg and tomato) as biological barriers for drug release. The study revealed that drug release from tomato membranes was retarded (as compared to egg membranes) but the release pattern matched that of egg membranes. All formulations followed the Baker-Lansdale model of drug release irrespective of the two different biological barriers. Stability studies were carried out for 45 days and exhibited less variation in particle size as well as a reduction in entrapment efficiency. Simvastatin loaded PEC stabilized nanoparticles exhibited better control on growth of human breast cancer cell lines than simple simvastatin. An unusual anticancer effect of simvastatin nanoparticles is also supported by several other research studies.
CONCLUSIONS: The present study involves first-time synthesis of Ch-TGP polyelectrolyte complex stabilized nanoparticles of simvastatin against MCF-7 cells. It recommends that, in future, theoretical modeling and IVIVC should be carried out for perfect designing of delivery systems.
METHODS: The antisolvent precipitation method was used for formulation of nanoparticles. Factorial design (32) was utilized as a tool to analyze the effect of Ch and TGP concentration on particle size and entrapment efficiency of nanoparticles.
RESULTS: Formulated nanoparticles showed high entrapment efficiency (67.19±0.42-83.36±0.23%) and small size (53.3-383.1 nm). The present investigation involved utilization of two biological membranes (egg and tomato) as biological barriers for drug release. The study revealed that drug release from tomato membranes was retarded (as compared to egg membranes) but the release pattern matched that of egg membranes. All formulations followed the Baker-Lansdale model of drug release irrespective of the two different biological barriers. Stability studies were carried out for 45 days and exhibited less variation in particle size as well as a reduction in entrapment efficiency. Simvastatin loaded PEC stabilized nanoparticles exhibited better control on growth of human breast cancer cell lines than simple simvastatin. An unusual anticancer effect of simvastatin nanoparticles is also supported by several other research studies.
CONCLUSIONS: The present study involves first-time synthesis of Ch-TGP polyelectrolyte complex stabilized nanoparticles of simvastatin against MCF-7 cells. It recommends that, in future, theoretical modeling and IVIVC should be carried out for perfect designing of delivery systems.
摘要：
目的：本研究旨在制备壳聚糖（Ch）-罗望子胶多糖（TGP）聚电解质复合物稳定的辛伐他汀立方纳米粒，并评估其对人乳腺癌细胞系的潜力。
方法:使用反溶剂沉淀法配制纳米颗粒。利用析因设计(32)作为工具来分析Ch和TGP浓度对纳米颗粒的粒径和包封效率的影响。
结果：配制的纳米颗粒显示出高包封率（67.19±0.42-83.36±0.23％）和小尺寸（53.3-383.1nm）。本研究涉及利用两种生物膜（鸡蛋和番茄）作为药物释放的生物屏障。研究表明，番茄膜的药物释放被延迟（与卵膜相比），但释放方式与卵膜的释放方式相匹配。所有制剂都遵循药物释放的Baker-Lansdale模型，而与两种不同的生物屏障无关。稳定性研究进行了45天,并且表现出颗粒尺寸的较小变化以及包封效率的降低。负载辛伐他汀的PEC稳定的纳米颗粒对人乳腺癌细胞系的生长表现出比简单辛伐他汀更好的控制。其他几项研究也支持辛伐他汀纳米颗粒的不寻常的抗癌作用。
结论：本研究涉及针对MCF-7细胞的Ch-TGP聚电解质复合物稳定的辛伐他汀纳米颗粒的首次合成。委员会建议,在未来,应进行理论建模和IVIVC，以实现输送系统的完美设计。
方法:使用反溶剂沉淀法配制纳米颗粒。利用析因设计(32)作为工具来分析Ch和TGP浓度对纳米颗粒的粒径和包封效率的影响。
结果：配制的纳米颗粒显示出高包封率（67.19±0.42-83.36±0.23％）和小尺寸（53.3-383.1nm）。本研究涉及利用两种生物膜（鸡蛋和番茄）作为药物释放的生物屏障。研究表明，番茄膜的药物释放被延迟（与卵膜相比），但释放方式与卵膜的释放方式相匹配。所有制剂都遵循药物释放的Baker-Lansdale模型，而与两种不同的生物屏障无关。稳定性研究进行了45天,并且表现出颗粒尺寸的较小变化以及包封效率的降低。负载辛伐他汀的PEC稳定的纳米颗粒对人乳腺癌细胞系的生长表现出比简单辛伐他汀更好的控制。其他几项研究也支持辛伐他汀纳米颗粒的不寻常的抗癌作用。
结论：本研究涉及针对MCF-7细胞的Ch-TGP聚电解质复合物稳定的辛伐他汀纳米颗粒的首次合成。委员会建议,在未来,应进行理论建模和IVIVC，以实现输送系统的完美设计。
